Niagen Bioscience
Niagen Bioscience's revenue rose 29.9% to $129 million in fiscal 2025. Its operating margin was 12.6%, up from 7.8% a year earlier. It paid out $0 million in dividends and buybacks. The diluted share count rose 9.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Niagen Bioscience does
Niagen Bioscience sells products built around nicotinamide riboside (NR), a form of vitamin B3 that helps the body make NAD+, a coenzyme found in every cell. It was formerly named ChromaDex and changed its name in March 2025. It says NAD+ levels fall with age, by up to 65% between ages 30 and 70.
It sells Niagen, its brand of NR, as a dietary and food ingredient, and it began selling it in 2013. Since 2017 it has sold Tru Niagen, a dietary supplement sold directly to consumers. In 2024 it launched Niagen Plus products, which contain pharmaceutical-grade Niagen. It also supplies pharmaceutical-grade Niagen to FDA-registered outsourcing facilities and compounding pharmacies abroad, which prepare and distribute injectable Niagen formulations, available only with a prescription.
It says its future success depends largely on sales of Tru Niagen. The company lists a history of operating losses and says it may need more financing.
Its biggest risks, as it describes them
- Relying largely on sales of one product, Tru Niagen.
- Competitors that are larger and have more resources, and pressure on its prices.
- Operating losses in the past, and possibly needing more financing.
- Depending on its own sales, marketing and distribution capabilities and on key personnel.
- Not being able to earn money from its products for pharmaceutical uses through partnerships or licensing.
Income statement
From fiscal 2024 to 2025, earnings per share grew 81.8% a year and net income 104.7% a year, as new shares raised the share count by 9% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 28 | 20 | 27 | 44 | 65 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −28 | −20 | −27 | −44 | −65 |
| Net debt to EBITDA | — | — | — | −5.2x | −3.8x |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −492.2x | −18,628.0x | −2,799.5x | 7,726.0x | 16,279.0x |
| Current ratio | 2.8x | 2.6x | 2.4x | 3.6x | 4.9x |
| Quick ratio | 2.0x | 1.8x | 1.7x | 3.1x | 4.4x |
Cash flow
Projections
Project Niagen Bioscience's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Niagen Bioscience says to expect
- Full year 2026: direct website and e-commerce revenue
For the full year 2026, the Company expects direct website revenues to grow by 15% to 20% year-over-year and overall e-commerce to grow by approximately 5% year-over-year.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $45,616 of Niagen Bioscience shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 2025 | Ozan PamirChief Financial Officer | Bought | 6,685 | $6.82 | $45,616 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 7 of 9 | 6 of 9 |
| Rule of 40 | — | — | — |
| Altman Z'' | −7.40 | −1.31 | 3.42 |
| Accruals ratio | −22.1% | −5.8% | 4.4% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 5 of 9 | 7 of 9 | 6 of 9 |
Compare
Put Niagen Bioscience side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Niagen Bioscience | FY25 | 29.9% | 12.6% | — | — | −3.8x | 6 | |
| The Honest Company | FY25 | −1.9% | −5.0% | 3.7% | — | — | — | Compare |
| Nature's Sunshine Products | FY25 | 5.7% | 5.2% | 6.0% | 23.6% | −2.4x | 7 | Compare |
| USANA Health Sciences | FY25 | 8.3% | 4.0% | 0.9% | — | — | — | Compare |
| Nu Skin | FY25 | −14.3% | 4.4% | 3.1% | 6.5% | −0.1x | 7 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 22 | 21 | 32 | 46 | 59 | 67 | 72 | 84 | 100 | 129 |
| Revenue growth | 21.1% | −2.1% | 48.9% | 46.7% | 28.0% | 13.8% | 6.8% | 16.0% | 19.2% | 29.9% |
| Gross profit | 10 | 10 | 16 | 26 | 35 | 42 | 43 | 51 | 62 | 83 |
| Research and development | 2 | 4 | 6 | 4 | 3 | 4 | 5 | 5 | 6 | 6 |
| Operating income | −3 | −16 | −33 | −31 | −20 | −27 | −19 | −6 | 8 | 16 |
| Net income | −3 | −11 | −33 | −32 | −20 | −27 | −16 | −5 | 8 | 17 |
| Diluted EPS (US$) | −0.08 | −0.26 | −0.61 | −0.56 | −0.33 | −0.40 | −0.24 | −0.07 | 0.11 | 0.20 |
| Diluted shares (millions) | 37 | 45 | 55 | 57 | 61 | 67 | 70 | 75 | 78 | 85 |
| Cash flow | ||||||||||
| Cash from operations | −3 | −10 | −21 | −20 | −11 | −24 | −15 | 7 | 12 | 14 |
| Capital expenditure | 2 | 1 | 1 | 1 | — | — | — | — | — | — |
| Free cash flow | −4 | −11 | −22 | −21 | — | — | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 5 | 6 | 7 | 7 | 6 | 6 | 5 | 4 | 6 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 2 | 45 | 23 | 19 | 17 | 28 | 20 | 27 | 44 | 65 |
| Debt incl. finance leases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total assets | 20 | 63 | 42 | 40 | 38 | 58 | 54 | 55 | 68 | 106 |
| Total liabilities | 10 | 9 | 15 | 20 | 22 | 26 | 25 | 26 | 22 | 30 |
| Shareholders' equity | 10 | 54 | 27 | 20 | 16 | 32 | 29 | 28 | 46 | 76 |
| Margins and ratios | ||||||||||
| Gross margin | 48.0% | 49.4% | 50.9% | 55.7% | 59.5% | 61.5% | 59.4% | 60.8% | 61.8% | 64.3% |
| Operating margin | −13.4% | −77.2% | −105.1% | −67.6% | −33.5% | −40.1% | −25.9% | −6.7% | 7.8% | 12.6% |
| Net margin | −13.5% | −53.7% | −105.6% | −69.5% | −33.6% | −40.2% | −23.0% | −5.9% | 8.6% | 13.4% |
| Free cash flow margin | −20.5% | −51.8% | −70.4% | −45.8% | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | 0.6% | −53.9% | −21.6% | 0.9% | — | — | — | — | — | — |
| Return on capital | −35.2% | −151.4% | −389.6% | — | — | — | −246.5% | — | — | — |
| Return on equity | −38.4% | −35.7% | −82.2% | −135.0% | −108.1% | −112.7% | −54.8% | −17.3% | 22.9% | 28.4% |
| Return on assets | −15.2% | −27.6% | −63.5% | −78.0% | −50.7% | −56.4% | −29.6% | −9.1% | 13.9% | 19.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | −5.2x | −3.8x |